

**LISTING OF CLAIMS:**

This listing of claims provided below will replace all prior versions and listings of claims in the application.

Claims 1-55 (Canceled).

56. (Previously Presented) A method of treating a viral infection in a subject in need of such treatment comprising administering to said subject an effective infection-combating amount of a compound of 3'-azido-3'-deoxy-5'-(3-dodecanamido-2-decyloxypropyl)-phosphothymidine, or a pharmaceutical salt thereof, wherein the viral infection comprises a virus selected from the group consisting of HIV-1, herpes virus, influenza, respiratory syncytial virus, mumps, measles, and parainfluenza virus.

Claims 57-68 (Canceled).

69. (Previously Presented) The method according to claim 56, wherein said viral infection is caused by HIV-1 virus.

70. (Canceled).

71. (Previously Presented) The method according to claim 56, wherein said viral infection is caused by herpes simplex virus.

Claims 72-106 (Canceled).

107. (Previously Presented) A method of treating a viral infection in a subject in need of such treatment comprising administering to said subject an effective infection-combating amount of a compound of 3'-azido-3'-deoxy-5'-(3-dodecyloxy-2-decyloxypropyl)-phosphothymidine or a pharmaceutical salt thereof, wherein the viral infection comprises a virus selected from the group consisting of HIV-1, herpes virus, influenza, respiratory syncytial virus, mumps, measles, and parainfluenza virus.

Claims 108-109 (Canceled).

110. (Previously Presented) The method according to claim 107, wherein said viral infection is caused by HIV-1 virus.

111. (Canceled).

112. (Previously Presented) The method according to claim 107, wherein said viral infection is caused by herpes simplex virus.

113. (Previously Presented) The method according to claim 56, wherein said subject is a human.

114. (Previously Presented) The method according to claim 56, wherein said administration is oral.

115. (Previously Presented) The method according to claim 56, wherein said administration is rectal.

116. (Previously Presented) The method according to claim 56, wherein said administration is topical.

117. (Previously Presented) The method according to claim 56, wherein said administration is intrathecal.

118. (Previously Presented) The method according to claim 56, wherein said administration is buccal.

119. (Previously Presented) The method according to claim 56, wherein said administration is parenteral.

120. (Previously Presented) The method according to claim 56, wherein said compound is administered in an amount of at least about 0.1 ng/kg to about 1 ng/kg.

121. (Previously Presented) The method according to claim 56, wherein said compound is administered in an amount of at least about 0.001  $\mu$ g/kg to about 0.1 g/kg.

122. (Previously Presented) The method according to claim 107, wherein said subject is a human.

123. (Previously Presented) The method according to claim 107, wherein said administration is oral.

124. (Previously Presented) The method according to claim 107, wherein said administration is rectal.

125. (Previously Presented) The method according to claim 107, wherein said administration is topical.

126. (Previously Presented) The method according to claim 107, wherein said administration is intrathecal.

127. (Previously Presented) The method according to claim 107, wherein said administration is buccal.

128. (Previously Presented) The method according to claim 107, wherein said administration is parenteral.

129. (Previously Presented) The method according to claim 107, wherein said compound is administered in an amount of at least about 0.1 ng/kg to about 1 ng/kg,

130. (Previously Presented) The method according to claim 107, wherein said compound is administered in an amount of at least about 0.001  $\mu\text{g/kg}$  to about 0.1  $\text{g/kg}$ .